Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Recruiting

Phase 2

HLA-Haploidentical SCTStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Sponsor:

University of Illinois at Chicago

Code:

NCT03121001

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 16 - 60

Healthy Volunteers: Not accepted

Interventions

ATG

fludarabine

cyclophosphamide

Total body irradiation

Stem cell infusion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-18. This information was provided to ClinicalTrials.gov by University of Illinois at Chicago on 2024-11-12.